Trials in Oregon.
31 APOE4-relevant Alzheimer’s trials run in Oregon — 12 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- Enrolled carriers, prior data unfavorableNCT00348309Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Heart trial, genotype not relevantNCT02884206Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
- Genetic risk study, APOE4 plausible focusNCT03676738Cohort Study of Risk Factors for Postoperative Cognitive Decline
This observational cohort study is tracking patients who undergo elective spine surgery under general anesthesia to see who develops cognitive decline…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- Open to carriers, not 4-specificNCT04070703Tai Ji Quan and Cognitive Function in Older Adults With Mild Cognitive Impairment
This trial is testing whether a specially designed Tai Ji Quan program can improve memory and thinking skills, as well as the ability to do two things at once,…
- Not relevant to APOE4 carriersNCT04165109Trial-Ready Cohort-Down Syndrome (TRC-DS)
This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
- Open to carriers, not 4-specificNCT04262206Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Genotype collected, carriers not excluded yetNCT04639050Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
This Phase 1 trial is testing a drug called RO7126209 — given by IV infusion — in people with early to moderate Alzheimer's who have confirmed amyloid buildup…
- Anti-amyloid drug — carriers face higher ARIA riskNCT05463731A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…
- Open to carriers, not 4-specificNCT05591027Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
This trial is testing a water extract of Centella asiatica, an herbal plant, given orally for 6 weeks to people with mild cognitive impairment or early…
- Lifestyle study, genotype not mentionedNCT05725668A Study of Dual-task Exercise Training to Prevent Falls Among Older Adults With Mild Cognitive Impairment
This trial is testing whether a specialized form of tai ji quan that adds mental challenges to physical movement can reduce falls in older adults with mild…
- Open to carriers, not 4-specificNCT05771844Home Sleep Therapy for Older Adults With MCI
This trial is testing a home-use device called SleepWISP that delivers gentle, non-invasive electrical stimulation to the brain during sleep. The goal is to…
- Observational only, genotype not requiredNCT05826457North American Prodromal Synucleinopathy Consortium Stage 2
This study is building a research foundation — enrolling people with REM sleep behavior disorder (RBD) and healthy controls to prepare for future trials of…
- Open to carriers, not 4-specificNCT06079190Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing two doses of an experimental drug called GSK4527226 against a placebo in people with early Alzheimer's disease, including those…
- Open to carriers, not 4-specificNCT06223360A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
This trial is testing benfotiamine — a fat-soluble form of vitamin B1 — at two different doses against a placebo, in people who already have early Alzheimer's…
- Caregiver study, genotype not relevantNCT06460012Support Via Technology: Living and Learning With Advancing Dementia-REVISED
This trial tests an online self-directed program called STELLA-R designed to help family caregivers manage the difficult behavioral and psychological symptoms…
- Open to carriers, not 4-specificNCT06721156A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
This trial is testing MK-1167, an experimental drug given alongside a standard Alzheimer's medication called an acetylcholinesterase inhibitor. Researchers…
- Open to carriers, not 4-specificNCT06847321Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
This Phase 2 trial is testing LHP588, an oral capsule taken once daily, in people with mild to moderate Alzheimer's disease who also test positive for P.…
- Open to carriers, not 4-specificNCT06976216A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
This trial is testing KarXT plus KarX-EC, a combination drug approach aimed at improving cognition in people who already have mild to moderate Alzheimer's…
- Genotype not mentioned, proceed cautiouslyNCT07094516A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
This trial is testing VHB937, a biological drug, in people with early Alzheimer's disease — either mild cognitive impairment or mild AD confirmed by…
- Anti-amyloid drug — carriers verify eligibilityNCT07170150A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
This trial is testing trontinemab, an anti-amyloid antibody drug given by injection, against a placebo in people with early Alzheimer's — from mild cognitive…
- Gateway study, genotype not specifiedNCT07177352Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
This is not a treatment trial. It is a pre-screening study run by Roche to figure out who might qualify for their future Alzheimer's disease trials.…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.